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Abstract: Myocardial tissue damage that occurs during an ischemic event leads to a spiraling
deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known
efficacious strategy and is the most commonly used treatment to reduce injury and prevent
remodeling. However, timing is critical, and the procedure is not always feasible for a variety
of reasons. The complex molecular basis for cardioprotection has been studied for decades but
formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive.
In this review, we address barriers to the development of a fruitful approach that will substantially
improve the prognosis of those suffering from this widespread and largely unmitigated disease.
Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important
criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection
that surpasses the limitations currently observed.
Keywords: myocardial infarction; cardioprotection; therapeutic strategies; ephrinA1; ischemia;
reperfusion
1. Introduction
Cardiovascular disease (CVD), a general term for heart dysfunction resulting from a wide range of
etiologies, is a significant health concern that has been the leading cause of death contemporaneously
and in recent history [1]. A heart attack, or myocardial infarction (MI), is one of the most common
occurrences that can either result from or cause CVD. According to the Fourth Universal Definition
of Myocardial Infarction, MI is defined as myocardial tissue injury detected by divergent cardiac
biomarkers and accompanied by evidence of ischemia. The cause of the injury does not preclude
designation as an MI [2]. In a clinical setting, patients with an MI are assessed to determine the degree
of the occlusion. A complete blockage is designated as an ST-segment elevation myocardial infarction
(STEMI) and represents the most serious type of MI. A heterogeneous level of blockage is termed a
non-ST-segment elevation myocardial infarction (NSTEMI) [3].
MI is a significant international health problem. Globally, the World Health Organization estimates
over 32 million MIs and strokes occur annually [4]. Notably, precise quantification of the mortality
attributable to MI is complicated by the lack of a universal standardized method to designate and
record MI related deaths. Despite this difficulty, the Global Health Data Exchange (GHDx) conducts an
annual Global Burden of Disease (GBD) study using the available international data. The most recent
GBD study grouped MI related deaths under an umbrella cause of death term- “ischemic heart disease”
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(IHD). The analyses of the data collected for this GBD study showed that IHD was a contributing
factor in almost 16% of deaths worldwide. These analyses also examined regional, socioeconomic, and
other demographic categorizations, and a subset of this data is shown in Table 1 [5].
Table 1. Ischemic heart disease related deaths in select demographics [5] *.













Latin America and Caribbean 14.05392127
Tropical Latin America 13.07831696






Central Sub-Saharan Africa 5.589027664
Southern Sub-Saharan Africa 6.811094508
Sub-Saharan Africa 4.942820494
North Africa and Middle East 24.78925909
Western Sub-Saharan Africa 4.443263763
Eastern Sub-Saharan Africa 4.873600872
* Includes males and females of all ages. Shown as percent (%) of total deaths in group. SDI = socio
demographic index.
An annual report published by the American Heart Association (AHA) gives a more granular
view of the incidence and mortality associated with MI in the United States (US). In the US over
750,000 adults per year are afflicted with an MI [6]. Furthermore, the survival rate of US adults
that have an out-of-hospital cardiac arrest (OHCA) and subsequently receive emergency medical
services for the MI is an abysmal 10–11% [7]. The high mortality rate in persons that experience
an OHCA epitomizes the urgent need for development of novel, acute therapeutic strategies to
prevent or repair myocardial tissue damage resulting from an MI. Moreover, the health and well-being,
productivity, longevity, and economic impacts of this irreversible condition are projected to worsen.
There is also significant variability in the incidence, prevalence, and mortality associated with MI with
respect to gender, ethnicity, comorbidities, socioeconomic status, and age [7]. Thus, more effective,
personalized strategies for reducing infarct size and ultimately reducing mortality from MI should be
vigorously pursued.
The scientific community is cognizant of the need to reduce MI-mediated tissue injury and its
impact on global cardiac function as evidenced by the considerable amount of research over the last
40 years dedicated to understanding the mechanisms by which cardiac tissue can be preserved in the
face of such stress (Figure 1). A wide range of experimental paradigms in various in vivo and in vitro
animal and cell culture models have led to the discovery of over 100 mediators of preconditioning
and postconditioning that can be affected both locally and remotely. Many pathways and molecules
ranging from lipids, hormones, ion channels, cytokines, enzymes, transcription factors, mRNAs,
and subcellular organelle function/production have been demonstrated to be involved in one or
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more processes that provide cellular protection from ischemia. To-date however, there have been no
formulation/administration of these mediators that have successfully reached the clinical realm.
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The morbidity and mortality suffered as a consequence of MI are positively correlated with 
infarct size. The region of heart affected is also related to the degree of morbidity and rate of survival 
from an MI because valve function may be compromised [8,9]. A clear threshold designating an 
infarct size that definitively improves survivability has not been established. However, a systematic 
analysis of data pertaining to infarct size, ejection fraction, and the rate of mortality following an MI 
demonstrated that achieving an infarct that is <20% of the left ventricle (LV) would likely result in an 
improved outcome [10]. Indeed, there are current pharmacotherapies that are unconventional 
treatments for MI but show evidence of improving the outcome of MI due to decreased scar formation 
and/or a reduction in infarct size. 
Ivabradine is currently used in a clinical setting as an antianginal agent and is effective at 
reducing heart rate [11–13]. Ivabradine has also been shown in rodent models of MI to significantly 
reduce scarring [14,15]. Another approach to reducing scar tissue in the infarcted heart is coaxing 
stem-cells to the damaged area. To this end, granulocyte colony stimulating factor (G-CSF) has been 
shown to attract stem cells from the bone marrow to damaged cardiac tissue and subsequently induce 
differentiation into mature cardiomyocytes and endothelial cells [16–18]. Metoprolol, a conventional 
β-blocker, has been shown to result in decreased infarct size when administered within a specific 
timeframe after the onset of ischemia [19,20]. 
The current treatment for MI depends on whether the patient is given a diagnosis of STEMI or 
NSTEMI [21]. A patient presenting with STEMI is always first prescribed reperfusion therapy. An 
initial diagnosis of NSTEMI, though, may result in a variety of alternative non-invasive or minimally 
invasive treatments to help ease the blockage [22]. This review focuses on addressing the unmet needs 
for therapies to improve STEMI outcomes given that a STEMI results in rapid, irreversible damage 
to cardiac tissue. It is widely accepted that reperfusion therapy given to a STEMI patient can generally 
slow the progression of heart failure. In the long-term, though, reperfusion does not restore healthy 
cardiac functionality or make significant gains in long-term survival [10]. This lack of efficacy is, at 
least in part, due to the time-sensitive nature of reperfusion therapy and the fact that on average 
reperfusion does not reduce infarct size to < 20% of the LV. In fact, reperfusion therapy results in a 































































Figure 1. Literature search on Pubmed for the terms related to cardiac ischemia tissue injury show
16,752 publications since 1978. Search details: (“heart”[MeSH Terms] OR “heart”[All Fields] OR
“cardiac”[All Fields]) OR (“ischaemia”[All Fields] OR “ischemia”[MeSH Terms] OR “ischemia”[All
Fields]) OR (“tissues”[MeSH Terms] OR “tissues”[All Fields] OR “tissue”[All Fields]) OR (“wounds
and injuries”[MeSH Terms] OR (“wounds”[All Fields] AND “injuries”[All Fields]) OR “wounds and
injuries”[All Fields] OR “injury”[All Fields]) AND (“1978/01/01”[PDAT]: “2018/11/29”[PDAT]):
https://www.ncbi.nlm.nih.gov/pubmed/; site visited on 29 November 2018.
The morbidity and mortality suffered as a consequence of MI are positively correlated with infarct
size. The region of heart affected is also related to the degree of morbidity and rate of survival from an
MI because valve function may be compromised [8,9]. A clear threshold designating an infarct size
that definitively improves survivability has not been established. However, a systematic analysis of
data pertaining to infarct size, ejection fraction, and the rate of mortality following an MI demonstrated
that achieving an infarct that is <20% of the left ventricle (LV) would likely result in an improved
outcome [10]. Indeed, there are current pharmacotherapies that are unconventional treatments for
MI but show evidence of improving the outcome of MI due to decreased scar formation and/or a
reduction in infarct size.
Ivabradine is currently used in a clinical setting as an antianginal agent and is effective at reducing
heart rate [11–13]. Ivabradine has also been shown in rodent models of MI to significantly reduce
scarring [14,15]. Another approach to reducing scar tissue in the infarcted heart is coaxing stem-cells to
the damaged area. To this end, granulocyte colony stimulating factor (G-CSF) has been shown to attract
stem cells from the bone marrow to damaged cardiac tissue and subsequently induce differentiation
into mature cardiomyocytes and endothelial cells [16–18]. Metoprolol, a conventional β-blocker, has
been shown to result in decreased infarct size when administered within a specific timeframe after the
onset of ischemia [19,20].
The current treatment for MI depends on whether the patient is given a diagnosis of STEMI or
NSTEMI [21]. A patient presenting with STEMI is always first prescribed reperfusion therapy. An
initial diagnosis of NSTEMI, though, may result in a variety of alternative non-invasive or minimally
invasive treatments to help ease the blockage [22]. This review focuses on addressing the unmet needs
for therapies to improve STEMI outcomes given that a STEMI results in rapid, irreversible damage to
cardiac tissue. It is widely accepted that reperfusion therapy given to a STEMI patient can generally
slow the progression of heart failure. In the long-term, though, reperfusion does not restore healthy
cardiac functionality or make significant gains in long-term survival [10]. This lack of efficacy is, at
least in part, due to the time-sensitive nature of reperfusion therapy and the fact that on average
reperfusion does not reduce infarct size to < 20% of the LV. In fact, reperfusion therapy results in a
median infarct size of 50% [10,23,24].
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There are many obstacles currently blocking the progress of treating MI in humans. For example,
pre-clinical models of MI largely fail to sufficiently replicate the conditions of human disease because
many pathologies are derived from complex etiologies and commonly occur as comorbidities in the
human patient population [25–27]. Concerns regarding time, dose/frequency, and delivery mode
also remain significant impediments to translation of candidates that have demonstrated pre-clinical
potential [28–30]. Notably, though, some recent advancements with regards to delivery were reported.
After a 32 month duration, follow-up with patients given percutaneous coronary interventions (PCI)
incorporating the use of second-generation drug-eluting stents (DES) were found to have comparable
outcomes to patients that received coronary artery bypass surgery (CABS) [31]. It remains to be
seen if PCI with second-generation DES is equally effective in the long-term and in patients with
specific pathologies. Long-term studies (5 years) comparing PCI incorporating first-generation DES
to CABS found a significant increase in major adverse cardiac and cerebrovascular events in the
PCI cohort compared to the CABS cohort [32]. In a long-term study (5-years) diabetic patients
with a DES implantation did not show any difference in rates of death, MI, or stroke than diabetic
patients that received CABS. However, the DES group did have a significantly higher rate of repeat
revascularization [33].
Recent research also suggests emerging therapies in the form of nutritional intervention for
improving the outcome of heart failure. The heart undergoes a metabolic phenotype shift during
the progression from ischemic insult to decompensated hypertrophy. The normal, healthy heart
overwhelmingly uses fatty acid oxidation (FAO) to generate ATP, which is the energy currency for
contraction [34]. However, when a pressure-overload stress occurs, as is the case with strain exerted on
surrounding cardiac myocytes from damaged myocardial tissue, the reliance on FAO to generate ATP
is decreased [35,36]. Recently, it was reported that under stressed conditions, like pressure overload,
the heart increasingly relies on ketone bodies as a fuel substrate [37]. Furthermore, the increased rate
of ketone oxidation was found to be an adaptive mechanism and when ketones were increasingly
made available to the heart, the function of the failing heart was significantly improved [38].
Overall, analyses of cardioprotective strategies employed thus far has propelled a hypothesis
that a singular targeted approach to treating myocardial ischemia-reperfusion injury is insufficient,
and a multifactorial treatment paradigm will provide better outcomes for patients [25]. One way
of implementing multifactorial treatment is to use a combination of therapies that have had at least
some success in the clinical realm. Indeed, this has been a successful approach in many trials thus
far and is reviewed in great detail elsewhere [25]. Another way to address the need to treat MI
with a multifactorial approach, is to use a single molecule that targets multiple pathways. One such
intervention that shows promise by conferring a benefit to the outcome of ischemia/reperfusion is
treatment with ephrin A1-Fc (EA1-Fc).
2. Pathophysiology of MI
When coronary occlusion occurs, cardiac myocytes are starved of oxygen. These terminally
differentiated cardiomyocytes become ischemic and quickly begin to undergo necrosis, apoptosis [39–41],
and/or autophagy [41–44]. The damage from an MI is rapid, with necrosis occurring within the first
40 min of blockage [42]. Despite the controversy surrounding the potential for cardiac repair using
endogenous or exogenous progenitor cells, significant obstacles regarding host integration, clinical
feasibility, and functional outcomes must be overcome. As such, once the necrotic tissue is removed,
fibroblasts deposit a non-contractile matrix of collagen, leading to scar formation. The scar tissue
is rigid and, combined with increased fibrosis in the viable portions of the myocardium, impairs
both the contractility and relaxation of the heart muscle, i.e., impaired diastolic filling and systolic
ejection [41,45–48].
To make matters worse, the systemic physiological response to ischemic stress causes
further damage. The immune system responds immediately to ischemia in the heart with
neutrophils infiltrating the oxygen-deprived tissue. Shortly after neutrophils have migrated to
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the ischemic zone, leukocytes (mostly macrophages) arrive and begin to facilitate digestion of
necrotic cells [39,41,46,49–51]. While the immune system is critical for tissue repair in terms of
remodeling to promote revascularization and scar formation, the neutrophils also release reactive
oxygen species (ROS), cytokines and chemokines, and proteolytic enzymes, which cause further
damage to surrounding cells and the intercellular matrix. Ultimately, this systemic response to
ischemia backfires and causes a larger infarct zone [41,42,45–48].
The fibrotic scar that replaces lost contractile myocardium following an ischemic event undergoes
continuous remodeling. The extracellular matrix (ECM) degrades in response to increased matrix
metalloproteinase (MMP) activity and the fragments generated play a role in propagation of the
inflammatory response as well as the deposition of replacement scar tissue, which itself evolves
from the early fibrin-based matrix to a collagen-based mature scar [52]. The dynamic changes in
composition of the ECM that occur in response to the polarization of immune cell subsets from the
pro-inflammatory to the resolution phase is also complex, as is the sequelae of fibroblast activation
and scar formation, both of which remain under intensive investigation [53–58]. Of note, the juncture
between the non-contractile scar and contractile viable myocardium creates strain, which, in animal
models with large MIs, is predisposed to rupture. The beat-to-beat tension placed on this region is not
often considered but requires special attention [59]. The scarred heart is subject to increased workload
to sustain adequate cardiac output. Under increased stress, the healthy, non-proliferative cardiac
myocytes also begin to hypertrophy leading to LV remodeling and subsequent chamber dilation. The
hypertrophied cardiac myocytes further exacerbate the already strained heart, and this, combined with
increased interstitial fibrosis, results in eventual inability for the contractile apparatus of the heart to
contract strongly enough to maintain sufficient circulatory blood flow (i.e., heart failure) [41,60–63].
Without sufficient blood flow, systemic oxygen deprivation leads to organ failure and eventual death.
Thus, if the initial infarct injury can be reduced, the downward spiral to heart failure and mortality
may be at least partially averted. Additionally, reductions in the initial infarct injury result in increased
preservation of 3D tissue structure, which is beneficial for surgical reconstruction [64].
3. Ephrin A1 Ligand Intramyocardial Injection is Cardioprotective
One of the most commonly employed strategies to develop a new therapeutic target is to
investigate what changes occur on a molecular level between the healthy and diseased state. To
this end, Dries, Kent, and Virag (2011) found that the gene expression profile of the infarcted heart
changed dramatically when compared to the healthy heart. Some of the changes that occurred in
this study included altered expression of ephrinA1 (EA1) and several EphA receptors. Transcript
levels of EA1 were reduced by 35% after MI while expression of Eph receptors A1, A3, and A7
were increased [41]. The observed opposite directionality of expression changes strongly suggested
decreased activation of the Eph receptors in the infarcted myocardium.
The hypothesis that decreased cardiomyocyte EA1 expression was a contributing factor to the
pathology of MI was tested by direct intramyocardial injection of recombinant EA1-Fc ligand into
the heart immediately following permanent occlusion of the left anterior descending coronary artery.
When EA1-Fc was administered at the time of MI onset, the damage to the heart was significantly
reduced at 4 days post-MI, leading to reduced infarct size, less necrosis, less ventricular dilation, and
less inflammation [41]. Histological examination revealed that the levels of endogenous EA1 in the
infarcted heart were situated exclusively in the healthy regions of the heart tissue including the border
zone of the infarcted region. Interestingly, in hearts treated with EA1-Fc, 4 days post-MI, endogenous
EA1 protein expression appeared in the infiltrating granulation tissue cells throughout the region of
the infarct. The levels of endogenous EA1 were maintained at levels present in healthy myocardium
when EA1-Fc is provided immediately following MI as well [41].
This effect combined with decreased endogenous EA1 in infarcted myocardium, suggests that
EA1-Fc is a cardioprotective molecule [41]. In addition to direct positive effects on the infarcted region
and surrounding myocardium, EA1-Fc administration directly after MI also improves biomarkers of
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MI severity. One such biomarker, cardiac troponin I (cTnI) is a well-known correlate to the size of
MI injury [41,65–70]. In fact, the clinical diagnosis of MI includes serum levels of cardiac troponin
exceeding the 99th percentile upper reference limit (URL) [2,71]. When cTnI values exceed the 99th URL
and fluctuate (rising and/or falling), the injury to the myocardium is considered acute. Conversely,
if there is <20% fluctuation in cTnI values, the injury to the myocardium is considered chronic [2]).
When EA1-Fc is injected acutely into the infarcted heart, levels of cardiac troponin I are decreased by
approximately 55%. In this study, cTnI levels were only assessed at one point in time (4-days post-
surgery and treatment) [41]. Studies to measure cTnI levels at various points in time are needed to
further elucidate the mechanism of benefit conferred by EA1 treatment.
Additional experiments conducted in an acute I/R model further support the hypothesis that
EA1 is a cardioprotective agent. Specifically, measurements of tissue viability and infarct regions
revealed a marked drop in necrotic tissue in EA1-Fc treated mice in response to acute ischemia and
reperfusion (30min I/24hr R) compared to vehicle control mice [42]. Analysis of heart function using
M-mode echocardiography showed that I/R mice treated with IgG-Fc control, had significantly lower
fractional shortening (FS) and ejection fraction (EF) compared to the sham controls. In contrast, mice
injected with EA1-Fc did not have significantly different FS or EF measurements compared to the
uninjured sham controls. Four days post-MI, vehicle control mice displayed further decreases in
FS and EF measurements indicating worsening heart function over time. Again, even after 4-days
of reperfusion, the I/R mice provided EA1-Fc injections did not have significantly different FS and
EF compared to the sham controls [42]. In addition to EA1, other ephrin ligands and receptors (B
family) have been reported to play a cardioprotective role as well [72], but there have been no further
investigations. The unique bidirectional signaling system combined with the potential expression
of multiple receptor subtypes in each cell type in cardiac tissue adds considerable complexity to
deciphering the mechanisms by which protection occurs. The potential for this system to be exploited
for the simultaneous attenuation/stimulation of multiple pathways that culminate in reduced injury
and deleterious remodeling remains under investigation.
4. Potential mechanisms for Ephrin A1-mediated cardioprotection
Substantial information about the physiological ephrin ligand-receptor interaction has been
uncovered in the last 30 years. Since ephrin tyrosine kinase receptor was discovered in 1987 [73]
research regarding the ephrin ligand-receptor interaction indicates characteristic bidirectional
signaling [41,74–77]. Once ephrin ligands bind their respective receptors, the receptor undergoes
autophosphorylation. Phosphorylation of the ephrin receptor then triggers endocytosis and subsequent
degradation of the ligand–receptor complex [78]. The administration of chimeric EA1-Fc in MI has a
profound effect on expression of ephrin ligands and receptors, which may provide insight into the
mechanism of cardioprotection. The potential effect of EA1 signaling on the healthy and infarcted
myocardium is summarized in Figure 2.
Eight EphA receptors are expressed in mice and two of these, EphA5 and EphA8, are not expressed
in the healthy mouse myocardium. Of the six Eph receptors expressed in healthy myocardium, EA1-Fc
affects expression levels of five of these (A1, A2, A3, A4, and A6), and as mentioned previously,
positively regulates endogenous EA1 ligand expression [41,42]. Ephrin ligands A2-A5 and ephrin B3
are expressed in the normal heart but levels of expression do not change in response to MI or EA1-Fc
treatment [41]. Ephrin signaling is known to be involved in a variety of cellular processes including
growth, differentiation, motility, and survival [41,77–81]. Notably, EA1 is the only ephrin ligand that
binds to all eight ephrin receptors expressed in mice, so all of the cellular processes influenced by
ephrin receptors, which are expressed on each cell type, are potential candidates for the mechanism
behind EA1-Fc-mediated cardioprotection [41].
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Figure 2. Potential Mechanisms of EA1-Fc Mediated Cardioprotection. Treatment with Ephrin A1-Fc
(EA1-Fc) in a mouse model of myocardial infarction (MI) was shown to alter expression of five Ephrin
receptors (EphA1-A4 and EphA6) as well as endogenous EA1 ligand when compared to the vehicle
treated MI group. Canonical ephrin signaling regulates a wide-variety of physiological processes. The
cardioprotective role of EA1-Fc may be attributed to ephrin signaling. In support of this, in the EA1-Fc
MI group, indicators of decreased apoptosis, increased autophagy, and decreased inflammation were
observed. The possibility also exists that EA1-Fc injection is cardioprotective through a mechanism
that is not normally attributed to ephrin signaling.
For example, there is strong evidence to suggest that EA1-Fc administration reduces apoptosis in
the infarcted heart. The amount of cleaved PARP with EA1-Fc treatment in MI is decreased compared
to the MI hearts treated with vehicle control [41]. Levels of cleaved PARP are positively correlated with
apoptosis [82–84]. Also, in this study Bcl-2-associated athanogene-1 (BAG-1) protein, which is known
to enhance Bcl-2 anti-apoptotic effects [85,86], had expression levels increased by approximately 54%
in the E 1-Fc treated group. EA1-Fc administration also resulted in increased phosphorylation of
AKT [41]. AKT signaling is known to regulate myocyte survival with an increase in pAKT/AKT being
indicative of increased survival [87–90].
Another possibility for consideration is that the benefit conferred by EA1-Fc administration
may be attributed to the role of ephrin signaling in autophagy. EA1-Fc treatment resulted in an
increase of LC3II/LC3I ratios and decreased pmTOR/mTOR ratios compared to IgG-Fc treated MI
counterparts [42]. The change in both of these ratios suggest an increase in autophagy, which would
carry the benefit of repairing damaged tissue as this process removes dysfunctional cellular components
and recycles them to produce energy [91–95].
Additionally, EA1 signaling has been shown to have a role in angiogenesis primarily by mediating
endothelial cell migration [41,96–98]. EA2, EA6, and EA7 receptors are also expressed on endothelial
cells and have been implicated in angiogenesis [41,99–102]. However, an angiogenic response was not
apparent in the E 1-Fc injected MI heart. No differences were observed in endothelial cell proliferation
or capillary density between vehicle controls and EA1-Fc treated hearts [41].
It is known that ephrin receptors are expressed at different levels in early and late stages of
inflammation, suggesting a role for these receptors in the inflammatory response [41,103]. Indeed,
it does appear that EA1-Fc does affect the inflammatory response in MI. Compared to vehicle
treated controls, EA1-Fc injected hearts had a 57% reduction in neutrophil density and a 21%
reduction in leukocyte density. Also, EA1-Fc injection reduced protein levels of nuclear factor
κ light-chain enhancer of activated B cells (NF-κB) [41]. NF-κB is known to be involved with
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mediating inflammation [49]. Taken together, these studies demonstrate robust multitarget properties
of ephrinA1-Fc that coordinately reduce injury and promote tissue survival.
5. Conclusions
Despite the massive need and corresponding effort exerted, finding a practical and efficacious
agent for cardioprotection has proven to be an elusive task. In 2010, the National Institutes of Health
established a “consortium for preclinical assessment of cardioprotective therapies”, otherwise known
as CAESAR to address the longstanding futility surrounding cardioprotection. The rationale was
to establish an infrastructure that would increase the rigor of scientific research such that proposed
cardioprotective molecules would likely succeed in efficacy [104]. However, despite this conceptually
valuable paradigm shift, no overtly effective, clinically relevant, cardioprotective agents have emerged.
Numerous factors likely contribute to the lack of progress with regards to rehabilitating damaged
myocardium. One factor may be that the treatment needs to be multi-faceted [25,105]. The
majority of known cardioprotective factors only influence one or two aspects of tissue injury and
recovery [30,106,107]. One study examined the effect of applying a combination of therapies to the
outcome on infarct size. This study found that using a combination of three major MI treatments
showed a 55% decrease in infarct size, far exceeding benefits typically obtained by a single therapeutic
intervention [108]. This combination treatment strategy is similar to the benefit observed with a single
EA1-Fc treatment. Acute treatment of MI with EA1-Fc ligand has similar profound effects in preclinical
studies. An average reduction of 50% infarct size comes from a single EA1-Fc treatment alone at the
time of coronary artery ligation and complete functional recovery in reperfused myocardium [41,42]
(Figure 3).
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The robust cardioprotection afforded by EA1-Fc treatment is in the early stages of research with
respect to mechanism and duration of protection. Much work in the discovery and development
phase of drug development remains before pre-clinical studies can begin. Of particular note, there
are outstanding questions regarding the route of administration, timing, and dose of the EA1-Fc
treatment. These issues must be investigated further before EA1-Fc can advance to pre-clinical
pharmacological research. The method/substance applied must coordinately influence the cascades
that promote protection and/or reduce injury at the cellular and molecular level of most, if not all,
cell types involved. Given the controversy and multidimensional nature of questions surrounding
the parameters of an optimal intervention, many unknowns still remain [25,29]. Additionally, there is
still debate throughout the cardiac research community regarding what magnitude of difference is
needed to establish efficacy and what endpoints should be used for this measure [109]. The traditional
measurement of infarct size may not be the best indicator for extrapolating therapeutic potential due to
Int. J. Mol. Sci. 2019, 20, 1449 9 of 14
differences in body size and heart rate. Instead, functional outcomes normalized to an uninjured control
may be a better metric. Another hurdle that EA1-Fc must overcome is discovery of the mechanism by
which it confers cardioprotection. It may be that EA1-Fc simply amplifies, inhibits, or maintains the
normal activity of EphA receptors. The possibility also exists, though, that the addition of exogenous
EA1-Fc ligand during the stress of I/R conveys its positive effects through an alternative mechanism.
Ultimately, uncovering the mechanism of EA1-Fc-mediated cardioprotection would allow great insight
into what processes can be targeted for future development and individualized MI treatments to
optimize clinical outcomes.
6. Patents
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